Apheresis platelets are more frequently associated with adverse reactions than pooled platelets both in recipients and in donors: A study from French hemovigilance data

Transfusion

Volumn 56, Issue 6, 2016, Pages 1295-1303

  Daurat, Aurélien ^a   Roger, Claire ^a   Gris, Jeanchristophe ^b   Daurat, Gérald ^b   Feissel, Michel ^c   Le Manach, Yannick ^d   Lefrant, Jean Yves ^a   Muller, Laurent ^a  

^a CENTRE HOSPITALIER   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; THROMBOCYTE CONCENTRATE;

ABDOMINAL PAIN; ALLERGIC REACTION; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANXIETY DISORDER; APHERESIS; APPARENT LIFE THREATENING EVENT; ARTICLE; BLEEDING; BLOOD TRANSFUSION REACTION; BRADYCARDIA; BRONCHOSPASM; CHILL; COUGHING; CRACKLE; CYANOSIS; DIARRHEA; DONOR; FEVER; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMATOMA; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; HYPOXEMIA; HYPOXIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MORTALITY RATE; NAUSEA; OUTCOME ASSESSMENT; PRURITUS; PURPURA; RASH; RECIPIENT; RESPIRATORY DISTRESS; TACHYCARDIA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; URTICARIA; VOMITING; WHEEZING; ADVERSE EFFECTS; BLOOD DONOR; BLOOD SAFETY; COMPARATIVE STUDY; CYTOLOGY; EPIDEMIOLOGICAL MONITORING; EPIDEMIOLOGY; FRANCE; MORTALITY; PROCEDURES; THROMBOCYTE; THROMBOCYTOPHERESIS;

BLOOD DONORS; BLOOD PLATELETS; BLOOD SAFETY; EPIDEMIOLOGICAL MONITORING; FRANCE; HUMANS; PLATELET TRANSFUSION; PLATELETPHERESIS;

EID: 84973102462     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13475     Document Type: Article

References (20)

1. Stroncek DF, Rebulla P., Platelet transfusions. Lancet 2007; 370: 427-38.
2. Kiefel V., Reactions induced by platelet transfusions. Transfus Med Hemother 2008; 35: 354-8.
3. Dumont LJ, Szczepiorkowski ZM., Pooled platelet concentrates or apheresis platelets? N Engl J Med 2013; 368: 1848-9.
4. Triulzi DJ, Assmann SF, Strauss RG, et al., The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 2012; 119: 5553-62.
5. Xiao W, Tormey CA, Capetillo A, et al., Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components. Vox Sang 2013; 105: 334-40.
6. Schrezenmeier H, Seifried E., Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; 99: 1-15.
7. French guidelines for the diagnosis of recipient adverse reactions. [Internet]. Saint-Denis: Agence nationale de sécurité du médicament et des produits de santé (ANSM); 2015 [cited 2015 Aug 28]. Available from: http://ansm.sante.fr/searchengine/general-search?SearchText=fiche+technique+effets+ind%C3%A9sirables.
8. Bilans et rapports d'activité [Internet]. Saint-Denis: Agence nationale de sécurité du médicament et des produits de santé (ANSM); 2015 [cited 2015 Sep 3]. Available from: http://ansm.sante.fr/Mediatheque/Publications/Bilans-Rapports-d-activite-Bilans-et-rapports-d-activite.
9. Hirayama F., Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol 2013; 160: 434-44.
10. Brown CJ, Navarrete CV., Clinical relevance of the HLA system in blood transfusion. Vox Sang 2011; 101: 93-105.
11. Tobian AA, Fuller AK, Uglik K, et al., The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion 2014; 54: 1523-9.
12. Andreu G, Vasse J, Sandid I, et al., Use of random versus apheresis platelet concentrates. Transfus Clin Biol 2007; 14: 514-21.
13. Enright H, Davis K, Gernsheimer T, et al., Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 2003; 43: 1545-52.
14. Tormey CA, Sweeney JD, Champion MH, et al., Analysis of transfusion reactions associated with prestorage-pooled platelet components. Transfusion 2009; 49: 1242-7.
15. Anderson NA, Gray S, Copplestone JA, et al., A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med 1997; 7: 33-9.
16. Levin E, Culibrk B, Gyöngyössy-Issa MI, et al., Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production. Transfusion 2008; 48: 2331-7.
17. Pillonel J, Brouard C, Laperche S, et al., Estimation quantitative du risque de contamination d'un don de sang par des agents infectieux. Transfus Clin Biol 2009; 16: 138-45.
18. Schrezenmeier H, Walther-Wenke G, Müller TH, et al., Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007; 47: 644-52.
19. Lafeuillade B, Eb F, Ounnoughene N, et al., Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008. Transfusion 2015; 55: 636-46.
20. 2014 Barcelona (2) [Internet]. Manchester (UK): IHN: International Haemovigilance Network; 2014 [cited 2014 Sep 29]. Available from: http://www.ihn-org.com/ihn-symposium/2014-barcelona-2/.